FindTrial
Sign In

Effects of the administrartion of two different dosages of eparin on activation of coagulation pathway and of fibrinolisis and on platenet function in patients with myocardial revascolarization open heart - ND

Effects of the administrartion of two different dosages of eparin on activation of coagulation pathway and of fibrinolisis and on platenet function in patients with myocardial revascolarization open heart - ND

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2007-001443-22-IT
Enrollment
Unknown
Registered
2007-03-27
Start date
2006-09-21
Completion date
Unknown
Last updated
2012-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients who are suitable candidates for off-pump myocardial revascularization MedDRA version: 9.1 Level: SOC Classification code 10007541 Term: Cardiac disorders

Interventions

Trade Name: EPARINA BMS 1FL 5ML 5000UI/ML Pharmaceutical Form: Solution for infusion INN or Proposed INN: EPARINA SODICA Concentration unit: IU international unit(s) Concentration type: equal Concentr

Sponsors

AZIENDA OSPEDALIERA OSPEDALE POLICLINICO CONSORZIALE
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients who are suitable candidates for off-pump myocardial revascularization Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Patients with coagulation disorders

Design outcomes

Primary

MeasureTime frame
Main Objective: To compare the effects of two different dosages of eparin on activation of coagulation pathway and of fibrinolisis and on platenet function in patients with myocardial revascolarization;Secondary Objective: To compare the effects of two different dosages of eparin on activation of coagulation pathway and of fibrinolisis and on platenet function in patients with myocardial revascolarization;Primary end point(s): Endogenous thrombin potenzial ETP , plasmatic level of PF1 2 measured with ELISA test—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026